Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1250
- Registration Number
- NCT07055607
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 125
- Registration Number
- NCT07052292
A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People
- Conditions
- Healthy VolunteersChronic Kidney Disease
- Interventions
- Drug: NNC0705-0001Drug: Placebo
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 116
- Registration Number
- NCT07029568
- Locations
- 🇳🇱
ICON - location Groningen, Groningen, Netherlands
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
- Conditions
- Healthy VolunteersSickle Cell DiseaseThalassemia
- Interventions
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT07023029
- Locations
- 🇺🇸
PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland, United States
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
- Conditions
- Obesity and Overweight
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 840
- Registration Number
- NCT07018544
- Locations
- 🇰🇷
MyongJi Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Yonsei Hanaro Clinic, Chungcheongnam-do, Korea, Republic of
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
- Conditions
- Obesity
- Interventions
- Drug: CagriSema (Cagrilintide B and Semaglutide I)Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- First Posted Date
- 2025-06-09
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600
- Registration Number
- NCT07011667
- Locations
- 🇺🇸
FDRC, Costa Mesa, California, United States
🇺🇸Linda Vista Health Care Ctr, San Diego, California, United States
🇺🇸Diablo Clinical Research, Inc., Walnut Creek, California, United States
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 144
- Registration Number
- NCT07010432
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight
- Conditions
- Diabetes Mellitus, Type 2Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT07004322
- Locations
- 🇨🇳
Peking University Third Hospital, Northern branch-Phase I, Beijing, Beijing, China
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
- First Posted Date
- 2025-05-19
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT06979375
- Locations
- 🇦🇺
Concord Repatriation General Hospital - Cardiology, Concord, New South Wales, Australia
🇦🇺Royal Adelaide Hospital Cardiovascular Clinical Trials, Adelaide, South Australia, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
- First Posted Date
- 2025-05-19
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT06979362
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Pima Heart and Vascular, Tucson, Arizona, United States
🇺🇸Valley Clinical Trials, Northridge, California, United States